Anticoagulation Forum/LinkedIn
Sep 5, 2025, 12:55
RENOVE and API-CAT Trials: Exploring Secondary VTE Prevention
Anticoagulation Forum shared on LinkedIn:
”Missed it live? The recording of our recent webinar ‘Secondary VTE Prevention: To Reduce or Not to Reduce? A Focus on RENOVE and API-CAT‘ is now available!
Watch it now on our Archived Webinars page.
Dive into one of the most debated questions in anticoagulation—when and how to reduce the dose.
Our expert panel breaks down results from the RENOVE and API-CAT trials, with practical insights you can apply in your practice right away.
What you’ll take away:
- DOAC dosing strategies for extended secondary VTE prevention
- Evidence-based guidance for individualized care
- Real-world tips from leading clinicians
Free for AC Forum members — and joining is quick and free.
Don’t miss the chance to catch up on this timely and dynamic discussion!”
Watch the webinar here.
Find the latest webinars and seminars on thrombosis featured in Hemostasis Today.
-
Jun 27, 2026, 01:31Alessio De Rose: Addressing Micronutrient Deficiencies in the Era of GLP-1 Receptor Agonists
-
Jun 27, 2026, 01:21Michelle Sámano Sánchez: Exploring Vitamin C as an Adjunct Therapy for Anemia in Hemodialysis
-
Jun 27, 2026, 01:08Ana Raquel Gotine: The First Pragmatic Clinical Trial on MNPs and Childhood Anemia in Mozambique
-
Jun 27, 2026, 00:56Sherif Badawy: Reflecting on My Time with ASH CRTI
-
Jun 27, 2026, 00:48Zain Khalpey: Why High quality CPR is Only Part of Successful Cardiac Arrest Management
-
Jun 26, 2026, 22:31Wendy Dusenbury: The New Issue of the Stroke Clinician is Now Live
-
Jun 26, 2026, 20:42Ed Watson: When It Happens to You, Stroke Becomes Personal, Immediate, and Life-Changing
-
Jun 26, 2026, 19:45Nathan Connell: Transforming Surgical Care with Tranexamic Acid
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?